Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL--Letter

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-0050
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

First-Line Ibrutinib Confirmed for CLL

Cancer Discovery
Oncology
2018English

Intracellular Single-Chain Antibody Inhibits Integrin VLA-4 Maturation and Function

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
1996English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Ibrutinib Also Inhibits ITK

Cancer Discovery
Oncology
2013English

Chemerin Contributes to Inflammation by Promoting Macrophage Adhesion to VCAM-1 and Fibronectin Through Clustering of VLA-4 and VLA-5

Journal of Immunology
AllergyImmunology
2010English

Biclonal IGHV -4-34 Variant Hairy Cell Leukemia and CLL - Successful Treatment With Ibrutinib and Venetoclax

American Journal of Hematology
Hematology
2018English

Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

Clinical Cancer Research
Cancer ResearchOncology
2019English

Ptbp1 Regulates Alternative Splicing of Apoptotic Protein: Implications in CLL and Ibrutinib Resistance

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ibrutinib Inhibits SDF1/CXCR4 Mediated Migration in AML

Oncotarget
Oncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy